Pacira BioSciences, Inc. (PCRX)

Cash ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cash and cash equivalents	US$ in thousands	276,774	245,965	247,053	184,052	153,298	99,119	86,810	35,545	104,139	109,424	122,061	226,751	585,578	134,036	105,774	66,699	99,957	125,244	78,552	54,589
Short-term investments	US$ in thousands	207,841	207,845	157,173	141,838	125,283	136,069	133,956	138,454	184,512	219,301	194,332	225,443	70,831	559,822	540,821	523,364	421,705	406,881	248,240	263,875
Total current liabilities	US$ in thousands	309,920	306,401	92,690	93,444	97,383	93,661	108,912	98,698	147,774	131,526	133,179	305,073	521,118	225,788	228,693	232,084	253,328	86,272	70,583	80,313
Cash ratio		1.56	1.48	4.36	3.49	2.86	2.51	2.03	1.76	1.95	2.50	2.38	1.48	1.26	3.07	2.83	2.54	2.06	6.17	4.63	3.97

December 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($276,774K + $207,841K) ÷ $309,920K
= 1.56

The cash ratio of Pacira BioSciences, Inc. has fluctuated over the years based on the provided data. The cash ratio measures a company's ability to cover its short-term obligations with its available cash and cash equivalents.

From March 31, 2020, to June 30, 2020, the cash ratio increased from 3.97 to 4.63, indicating an improvement in the company's liquidity position. The ratio further improved to 6.17 by September 30, 2020, suggesting a significant increase in the company's ability to meet its short-term obligations.

However, there was a notable decline in the cash ratio by December 31, 2020, dropping to 2.06. This decrease in the ratio indicates a potential decrease in the company's liquidity position during that period. The trend continued in the following quarters, with the ratio staying relatively low until March 31, 2021, when it slightly increased to 2.54.

Throughout 2021 and the first half of 2022, the cash ratio showed some improvement, reaching 2.83 by June 30, 2021, and further increasing to 2.50 by September 30, 2022. However, the ratio dipped again to 1.26 by December 31, 2021, marking a significant decrease in liquidity.

Subsequently, the cash ratio began to recover, reaching 2.38 by June 30, 2022, and increasing to 2.86 by December 31, 2023. The ratio continued to improve in the following quarters, peaking at 4.36 by June 30, 2024, indicating a substantial improvement in the company's liquidity position. However, by September 30, 2024, the ratio dropped back down to 1.48 before slightly increasing to 1.56 by December 31, 2024.

Overall, the cash ratio of Pacira BioSciences, Inc. has shown variability over the years, with periods of both improvement and decline in its liquidity position. Investors and analysts may monitor this ratio closely to assess the company's ability to meet its short-term financial obligations using its available cash resources.